Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 805-807, 2005; 10.1373/clinchem.2005.048017
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bradwell, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bradwell, A. R.
Related Collections
Right arrow Cancer Diagnostics (since 2002)
Right arrow Hematology
(Clinical Chemistry. 2005;51:805-807.)
© 2005 American Association for Clinical Chemistry, Inc.

Editorials

Serum Free Light Chain Measurements Move to Center Stage

Arthur R. Bradwell

Department of Immunity and Infection, The Medical School, University of Birmingham, Birmingham B15 2TT, United Kingdom, and, The Binding Site Ltd., Birmingham B14 4ZB, United Kingdom, E-mail A.R.BRADWELL@bham.ac.uk

The first 300 words of the full text of this article appear below.

For more than 150 years, the presence of Bence Jones protein [immunoglobulin free light chains (FLCs)] in the urine has been an important diagnostic marker for multiple myeloma. Indeed, it was the first cancer test, and 100 years before any others (1). Over the last few years, however, interest in FLCs has undergone a renaissance. Development of serum tests for free {kappa} and free {lambda} has opened the door to new applications and increased their clinical importance (2). By way of comparison, the management of diabetes mellitus was hugely improved when blood replaced urine for glucose analysis.

The report by Katzmann et al. (3) in this issue of Clinical Chemistry adds valuable confirmatory data on serum FLC testing. It is the first report of the assays being used in routine clinics with analysis of results on 1020 samples. As the authors point out, the performance of the tests has matched up to the retrospective studies that have been published previously.

From a physiologic viewpoint, blood tests for small proteins have clear advantages over urine tests. Serum FLCs are cleared rapidly through the renal glomeruli with a serum half-life of 2–6 h and are then metabolized in the proximal tubules of the nephrons. Under ordinary circumstances, little protein escapes to the urine (4), and serum FLC concentrations have to increase manyfold before the absorption mechanisms are overwhelmed. This makes urinalysis a fickle witness to changing FLC production. Conversion to a serum test provides clarity in assessing disease processes that were previously hidden from view.

Serum concentrations of FLCs are dependent on the balance between production (by plasma cells and their progenitors) and renal clearance. When there is increased polyclonal immunoglobulin production and/or renal impairment, both {kappa} and {lambda} FLC concentrations can increase 10- to 20-fold. However, the . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 BloodHome page
P. Zhou, J. Teruya-Feldstein, P. Lu, M. Fleisher, A. Olshen, and R. L Comenzo
Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan
Blood, January 15, 2008; 111(2): 549 - 557.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M. A. Gertz, M. Q. Lacy, A. Dispenzieri, S. R. Hayman, S. K. Kumar, N. Leung, and D. A. Gastineau
Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response
Haematologica, October 1, 2007; 92(10): 1415 - 1418.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. A. Katzmann
Serum Free Light Chain Specificity and Sensitivity: A Reality Check
Clin. Chem., September 1, 2006; 52(9): 1638 - 1639.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. G. Hill, J. M. Forsyth, B. Rai, and S. Mayne
Serum Free Light Chains: An Alternative to the Urine Bence Jones Proteins Screening Test for Monoclonal Gammopathies
Clin. Chem., September 1, 2006; 52(9): 1743 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. M. S. Muller, A. Geibel, H. P. H. Neumann, A. Kuhnemund, A. Schmitt-Graff, J. Bohm, and M. Engelhardt
Primary (AL) Amyloidosis in Plasma Cell Disorders
Oncologist, July 1, 2006; 11(7): 824 - 830.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.